Zentiva AG Acquires Major Stake in APONTIS PHARMA AG

Zentiva AG, based in Frankfurt, has finalized its voluntary public purchase offer for APONTIS PHARMA AG. This acquisition grants Zentiva control of approximately 83.57% of APONTIS PHARMA's share capital and 85.27% of its voting rights. Following the completion of the offer, APONTIS PHARMA shares will be delisted from the open market without a separate delisting offer.

The acceptance period for the offer has ended. Shareholders interested in selling their shares are encouraged to reach out via the provided contact information. Further details about the acquisition can be found on Zentiva's official offer website.